AVI BioPharma, Inc. (NASDAQ: AVII)

AVI BioPharma, Inc. (NASDAQ: AVII) is committed to discovering and developing RNA-based drugs using its expanded portfolio of proprietary antisense compounds. Functional attributes of their unique approach may include correcting genetic defects, coding for novel soluble receptors, and the reduction in activity of immune modulators in disease states. Additionally, the company’s RNA-based drug programs include blocking mRNA translation. For further information, visit the Company’s web site at www.avibio.com.